References

1. Larm O, et al. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Dev Art Org 1983;11:161-8.
2. Svenmarker S, et al. Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits. Eur J Cardiothorac Surg 2001;19:47-53.
3. Mahoney CB, et al. Transfusion after coronary artery bypass surgery: the impact of heparin bonded circuits. Eur J Cardiothorac Surg 1999;16:206-210.
4. Elgue G, et al. Effect of surface-immobilized heparin on the activation of adsorbed Factor XII. Artif Organs 1993;17:721-726.
5. Videm V, et al. In-vitro comparison of the heparin-coated and uncoated oxygenator circuits and 50% reduction of heparin dose. J Thorac Cardiovasc Surg 1991;101:654-6.
6. Larm O, et al. An approach to anti-thrombosis by surface modification. Progress in Artificial Organs 1985. Cleveland: ISAIO Press 1986;313-8.
7. Olsson P. Non-thrombogenic systems for extracorporeal gas exchange. Int J Artif Organs 1990;13:9.
8. Larsson R, et al. The search for thromboresistance using immobilized heparin. Blood in contact with natural and artificial surfaces. Ann NY Acad Sci 1987;516:102-115.
9. Belboul A, et al. Does heparin coating improve biocompatibility?: A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion 1997;12:385-391.
10. Borowiec J, et al. Effects of heparin-coating of cardiopulmonary bypass circuits on leukocytes during simulated extracorporeal circulation. Cardiovasc Surg 1997;5:568-73.
11. Kagisaki K, et al. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass. Artif Organs 1997;21:836-40.
12. Lundblad R, et al. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:1361-7.
13. Videm V, et al. Reduced granulocyte activation with heparin coated device in an invitro model of cardiopulmonary bypass. Artif Organs 1991;15:90-5.
14. Borowiec J, et all. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass - a clinical study. J Thor Cardiovasc Surg 1992;104:642-7.
15. Fukutomi M, et al. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. Artif Organs 1996;20:767-76.
16. Mollnew T, et al. Formation of C5a during cardiopulmonary bypass. Ann Thorac Surg 1991;52:92-7.
17. Mahoney CB. Heparin-bonded circuits: clinical outcomes and costs. Perfusion 1998;13:192-204.
18. Okkema AZ, et al. Physical and blood contacting characteristics of propyl sulphonate grafted biomer. Biomaterials 1991;12:3-12.
19. Grasel TG, et al. Properties and biological interactions of polyurethane aniomers: effect of sulfonate incorporation. J Biomed Mater Res 1989;311-338.
20. Lelah MD, et al. Polyether-urethane ionomers: surface property/ex vivo blood compatibility relationships. J Colloid Interface Sci 1985;104:422-439.
21. Silver JH, et al. Anticoagulant effects of sulphonated polyurethanes. Biomaterials 1992;13:339-343.
22. Charef S, et al. Heparin-like functionalized polymer surfaces: discrimination between catalytic and adsorption processes during the course of thrombin inhibition. Biomaterials 1996;17:903-912.
23. Han DK, et al. Heparin-like anticoagulant activity of sulphonated poly(ethelene oxide) and sulphonated poly(ethylene oxide)-grafted polyurethane. Biomaterials 1995;16:467-471.
24. Silver JH, et al. Anticoagulant effects of sulphonated polyurethanes. Biomaterials 1992;13:339-343.
25. Santerre JP, et al. Effect of sulfonation of segmented polyurethanes on the transient adsorption of fibrinogen from plasma: possible correlation with anticoagulant behaviour. J Biomed Mater Res 1992;26:39-57.
26. Lee JH, et al. Blood compatibility of polyethylene oxide surfaces. Prog Polym Sci 1995;20:1043-1079.
27. Lee JH, et al. Platelet adhesion onto segmented polyurethane film surfaces modified by addition and crosslinking of PEO-containing block copolymers. Biomaterials 2000;21:683-691.
28. Lee JH, et al. Blood compatibility of polyethylene oxide surfaces. Prog Polym Sci 1995;20:1043-1079.
29. Lee JH, et al. Platelet adhesion onto segmented polyurethane film surfaces modified by addition and crosslinking of PEO-containing block copolymers. Biomaterials 2000;21:683-691.
30. Dickinson T, et al. Trillium® -coated oxygenators in adult open-heart surgery: a prospective randomized trial. JECT 2002;34;248-253.
31. Palanzo DA, et al. Effect of Carmeda¨ BioActive Surface coating versus Trillium® Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass. Perfusion 2001;16:279-283.
32. Palanzo DA, et al. Effect of Trillium® Biopassive Surface coating of the oxygenator on platelet count drop during cardiopulmonary bypass. Perfusion 1999;14:473-479.
33. Cazzaniga A, et al. Trillium® biopassive surface: a new biocompatible treatment for extracorporeal circulation circuits. Int J Artif Organs 2000;23:319-24.
34. Baksaas ST, et al. In vitro evaluation of new surface coatings for extracorporeal circulation. Perfusion 1999;14:11-19.
35. Tevaearai HT, et al. Trillium coating of cardiopulmonary bypass circuits improves biocompatibility. Int J Artif Organs 1999;22:629-634.

Carmeda^® manufactured under license from Carmeda AB, Sweden. Carmeda is a registered trademark of Carmeda AB.

Trillium® Biosurface technology licensed under agreement from BioInteractions, Limited, United Kingdom.